JPM26: Sanofi’s COAST 1 clinical trials exhibit positive results, with researchers optimistic for COAST 2 results for amlitelimab
Sanofi's amlitelimab has shown promise in the Phase III COAST 1 trial, but data from the COAST 2 study is yet to be announced.


Patient-centric approaches thrive on wearables and remote access in trials
Pharma’s AI prospects get nudged into the future with EU’s AI act
Are regulators keeping pace with AI adoption in clinical trials?
AI-automated IVF procedures represent a new era in fertility treatment